Biopharma only testing - Insights
Find out how our suite of BioPharma Diagnostics-specific neurology testing can provide answers for your patients.
central_nervous_system_demyelinating_disease_diagnostic_algorithm.pdf
10/2024© Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. Central Nervous System Demyelinating Disease Diagnostic Algorithm* * For diagnosis of pediatric patients, see the Pediatric Autoimmune Central...
MCL Molecular Genetics SERPINA1 Gene Patient Information MC1235299
MCL Molecular Genetics SERPINA1 Gene Patient Information Complete print Reset Form Molecular Genetics SERPINA1 Gene Patient Information Instructions Accurate interpretation reporting genetic results
pediatric-autoimmune-cns-demyelinating-disease-diagnostic-algorithm.pdf
10/2024© Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. Pediatric Autoimmune Central Nervous System Demyelinating Disease Diagnostic Algorithm NEGATIVE PRESENT PRESENT ABSENT ABSENT Diagnosis:...
CPT codes and LOINC update: April 2024 - Insights
This page includes updates posted to Mayo Clinic Labs during the month of April.
October 2023 - Breast Pathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Breast Pathology.
CPT Codes and LOINC Update: Jan. 2019 - Insights
The list of updates posted to mayocliniclabs.com during the month of January 2019 are now available.
December 2022 - Pulmonary - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Pulmonary Pathology.
June 2023 - Clinical Chemistry - Insights
This "Pathways" program provides a Clinical Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Clinical Chemistry.
Mayo Clinic Laboratory and pathology research roundup: January 25 - Insights
Today's Topic Features: Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.